ClinicalTrials.gg
CompletedNCT01360749Updated Apr 13, 2012

Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal

A Phase 2 interventional study of Lambdalina® (Lidocaine 4% cream) and Placebo in Local Anesthesia, sponsored by ISDIN. Completed at 2 sites in Spain. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-13.

Sponsored by ISDIN · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Double-blind, randomized, placebo-controlled trial to assess the efficacy of Lambdalina (lidocaine cream) in reducing pain associated with laser hair removal in women.

02

Conditions studied

  • Local Anesthesia

Keywords

  • Pain management
  • Lidocaine
03

In context

Lead sponsor

ISDIN is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women ≥ 18 and ≤ 65 years old.
  2. Laser hair removal treatment session in the legs in the area from the knee to the ankle (first or second application).
  3. Able of accomplishing the study's requirements.
  4. Negative result in the pregnancy test.
  5. Sterile or surgically sterilized women (hysterectomy, tubal ligation) or using adequate methods.
  6. Written prior to inclusion in the trial.

Exclusion criteria

Exclusion Criteria:

  • General exclusion criteria:
  1. Pregnant or breastfeeding.

    • Current or previous medical conditions:
  2. Skin type 5 or 6 or a history of photosensitivity.
  3. Cardiovascular diseases such as unstable angina, or severe heart failure ( III or IV).
  4. Neuropathy or paresthesia.
  5. History of hepatic failure.
  6. diseases.
  7. Allergies to peanuts and/or soy and/or any components of the formulation.
  8. Use or dependence on prohibited substances.
  9. Other specified in the summary of product characteristics.

    • Current or previous concomitant medications:
  10. Any anesthetic or analgesic treatment during 2 hours prior of study entry.
  11. Concomitant treatment with antiarrhythmic drugs of class I (eg. tocainide, mexiletine) or class III (eg. amiodarone, sotalol), anticoagulants, anti- aggregating and/or beta-blockers.
  12. Active wounds or irritations in the area to be treated.
  13. Topical treatment with or other topical agent in the area to be studied.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Lambdalina and placebo

    Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.

    Drug: Lambdalina® (Lidocaine 4% cream) · Drug: Placebo

  • Experimental
    Placebo and lambdalina

    Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.

    Drug: Lambdalina® (Lidocaine 4% cream) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in pain intensity (Pain Visual Analogue Scale) associated to laser hair removal from baseline to the end of laser hair removal session (primary endpoint)

    Time frame: 30 minutes after treatment

Secondary outcomes

  1. Safety assessments including AEs and SAEs

    Time frame: 48 hours after treatment

07

Study locations

2 sites
  • Clínica Dermatológica Campo De Felipe
    Barcelona, Spain
  • Clínica Dermatológica Láser
    Madrid, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2011
First posted
May 26, 2011
Start
May 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Last update
Apr 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01360749
Lead sponsor
ISDIN
Responsible party
Sponsor
First posted
May 26, 2011
Start date
May 2011
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Apr 13, 2012

Study contacts

Antonio Campo Voegeli, MD
study chair · Clínica Dermatológica Campo De Felipe, Barcelona, Spain
Serafín Fernández, MD
principal investigator · Clínica Dermatológica Láser, Madrid, Spain
Antonio Campo Voegeli, MD
principal investigator · Clínica Dermatológica Campo De Felipe, Barcelona, Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion